Linked Life Data

341907

Source:http://linkedlifedata.com/resource/pubmed/id/341907

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1978-3-10
pubmed:abstractText
Z-1-(4-Bromophenyl)-1-(3-pyridyl)-3-dimethylaminopropene dihydrochloride hydrate (zimelidine; H 102/09), a newly developed bicyclic substance, was tested in a pilot study for its clinical effect in 10 female patients with a depressive syndrome. Zimelidine inhibits the 5-hydroxytryptamine (5-HT) reuptake more potently than does chlorimipramine. The action on the norepinephrine reuptake is weaker compared with imipramine, also the cardiotoxic and anticholinergic effects are lower. Zimelidine was administered for 20 days in a daily dose of 150 mg. A significant (p less than 0.05) improvement from the beginning of the treatment to the 15th day was demonstrated in Hamilton rating scale and a self-rating scale (von Zerssen). Nevertheless, the zimelidine treatment had to be discontinued between the 15th and 18th days in 3 patients, because of agitation symptoms. The antidepressant action in some patients justifies the performance of controlled studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0004-4172
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2421-3
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1977
pubmed:articleTitle
Effect of zimelidine (H 102/09) in depressive patients.
pubmed:publicationType
Journal Article, Clinical Trial